Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective
Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. We identify three main uses of patient preference studies along a technology’s pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefit-risk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies. In the context of the National Institute for Health and Care Excellence’s methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling. Rather, we see a role for patient preference studies to be submitted alongside other types of evidence. Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important non-health benefits or when a treatment is indicated for a heterogenous population.
JCB wrote the first draft of the manuscript. LC, RL, DM, HL and NC wrote parts of the manuscript. All authors reviewed and approved the final version of the manuscript.
Compliance with Ethical Standards
No funding was received for the preparation of this article.
Conflict of interest
Jacoline Bouvy, Luke Cowie, Rosie Lovett, Deborah Morrison, Heidi Livingstone and Nick Crabb have no conflicts of interest that are directly relevant to the content of this article.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Cowie L, Bouvy J. Measuring patient preferences: an exploratory study to determine how patient preferences data could be used in health technology assessment (HTA). Myeloma UK, 2019. Available from: https://www.myeloma.org.uk/wp-content/uploads/2019/07/NICE-Patient-Preferences-Report.pdf. Accessed 30 Oct 2019.
- 2.National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed 30 Oct 2019.
- 11.Postmus D, Mavris M, Hillege HL, Salmonson T, Ryll B, Plate A, et al. Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators. Clin Pharmacol Ther. 2016;99(5):548–54.CrossRefGoogle Scholar
- 12.Institute for Quality and Efficiency in Health Care. Choice-based conjoint analysis: pilot project to identify, weight, and prioritize multiple attributes in the indication “hepatitis C”. Working paper (English summary). 2014. Available from: https://www.iqwig.de/en/projects-results/projects/health-economic/ga10-03-pilot-study-conjoint-analysis-in-the-indication-hepatitis-c.1411.html. Accessed 13 Sept 2019.
- 13.National Institute for Health and Care Excellence. NICE provides first scientific advice on patient preference study design. 2019. Available from: https://www.nice.org.uk/news/article/nice-provides-first-scientific-advice-on-patient-preference-study-design. Accessed 30 Oct 2019.
- 14.IMI PREFER. About PREFER. 2019. Available from: https://www.imi-prefer.eu/about/. Accessed 30 Oct 2019.
- 15.National Institute for Health and Care Excellence. Our research work. 2019. Available from: www.nice.org.uk/research. Accessed 30 Nov 2019.